Immuneering Corp (IMRX)
1.39
+0.01
(+0.72%)
USD |
NASDAQ |
May 31, 16:00
1.39
0.00 (0.00%)
After-Hours: 20:00
Immuneering Research and Development Expense (TTM): 42.62M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 42.62M |
| December 31, 2023 | 41.62M |
| September 30, 2023 | 39.59M |
| June 30, 2023 | 38.90M |
| March 31, 2023 | 37.43M |
| December 31, 2022 | 36.28M |
| September 30, 2022 | 34.35M |
| Date | Value |
|---|---|
| June 30, 2022 | 31.20M |
| March 31, 2022 | 30.21M |
| December 31, 2021 | 26.54M |
| September 30, 2021 | 23.48M |
| June 30, 2021 | 21.34M |
| March 31, 2021 | 17.57M |
| December 31, 2020 | 15.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
15.00M
Minimum
Dec 2020
42.62M
Maximum
Mar 2024
31.15M
Average
32.78M
Median
Research and Development Expense (TTM) Benchmarks
| Geron Corp | 127.20M |
| SELLAS Life Sciences Group Inc | 21.94M |
| Elicio Therapeutics Inc | 25.92M |
| ADMA Biologics Inc | 2.895M |
| Outlook Therapeutics Inc | 34.08M |